NasdaqGS:DNLIBiotechs
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration
Why Denali’s recent earnings and shelf registration matter for shareholders
Denali Therapeutics (DNLI) has drawn fresh attention after reporting a wider fourth quarter and full year 2025 loss alongside a new US$200.7 million shelf registration for common stock, raising questions about dilution and funding plans.
For the fourth quarter, Denali reported a net loss of US$128.55 million, with basic and diluted loss per share from continuing operations of US$0.73, compared with US$0.67 a year...